A short general post notes the investigational triple agonist has shown strong trial results but can cause side effects. Thin on detail.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
BusinessWorld Online makes the case that Ozempic shouldn't be thought of as a weight loss drug. Only the headline was available, so tap through for the full argument.
Novo is putting oral treatments and more personalized options first as the market moves past raw weight loss numbers, the CEO told Chosun Ilbo.
Loading…